Michael Halstead, the newly appointed CEO of Helus Pharma, has a strong background. He has steered biopharmaceutical companies toward valuable exits. His role in the 2025 US$14.6 billion acquisition is a major career highlight. Intra-Cellular Therapies was acquired by Johnson & Johnson. During his time at Intra-Cellular, Halstead was actively involved in the development of CAPLYTA. The drug was successfully commercialized and is now approved for schizophrenia. It is also used for bipolar depression and as an adjunct treatment. CAPLYTA treats major depressive disorder. Helus is pursuing a similar target with its lead compound, HLP003. This compound could become a significant innovation in depression treatment.
Before joining Intra-Cellular, Halstead held key leadership roles at Warner Chilcott. He oversaw major strategic decisions during his tenure. In 2009, he managed the US$3 billion acquisition of Procter & Gamble’s pharmaceutical division. This move expanded the company’s product offerings significantly. Later, in 2013, he led Warner Chilcott through a US$8.5 billion sale to Actavis. The sale marked a major industry milestone. These accomplishments showcase his deep insight into managing biotech companies. He has experience with financial, regulatory, and operational elements. His expertise will be crucial for Helus as it approaches clinical milestones.
Helus at a Pivotal Moment
The timing of Halstead’s appointment is well-calibrated to align with Helus’ pivotal moment. The company is moving toward the final phase of the APPROACH trial. APPROACH is part of the broader PARADIGM program. The program is evaluating HLP003 as an adjunctive treatment for Major Depressive Disorder. Topline results from this key Phase 3 study are expected in the fourth quarter of 2026. Enrollment for APPROACH has already been completed. The second pivotal trial, EMBRACE, is currently ongoing. Participants are also being transitioned into EXTEND. EXTEND is a long-term extension study. It is providing further data on the compound’s effects over extended periods.
HLP003, Helus’ lead development asset, is a proprietary novel serotonergic agonist. It has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration. The designation is for use as an adjunct in treating major depressive disorder. This status is reserved for therapies that could offer substantial improvements. These therapies could offer improvements over available options. The designation may allow for accelerated regulatory review. With Halstead now at the helm, Helus is poised to move into a critical phase. It could unlock its first major commercial opportunity. Helus may establish itself in the psychiatric drug sector.
Why This Hire Matters for Helus’ Positioning
Strengthening Helus' Position
The appointment of Halstead reflects Helus’ dedication to growing its operations and preparing for the next stage of development. His career has been marked by his ability to commercialize pharmaceutical products and manage complex capital market strategies. As Helus advances, it needs a leader who can handle not only the upcoming clinical data release but also the infrastructure necessary for a successful product launch. Eric So, Helus’ co-founder and executive chairman, highlighted the importance of this appointment in guiding the company through its evolving clinical, regulatory, and commercial phases.
In addition to its strong clinical program, Helus has a well-developed intellectual property position. The company holds over 100 granted patents and has filed more than 350 patent applications worldwide, which strengthens its competitive edge in the mental health market. While HLP003 is the focus now, the company is also working on HLP004 for generalized anxiety disorder, adding another potential growth avenue. With Halstead’s leadership and a solid foundation in place, Helus is positioning itself to become a key player in the evolving field of mental health treatments.